Business Context and Reporting Period
This Form 8-K was filed by Abbott Laboratories on February 18, 2011. The report addresses a corporate governance change regarding the company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is not a financial earnings statement.
Material Changes
- Board Size Reduction: The Board of Directors amended Article III, Section 2 of the company's by-laws.
- Current Status: The Board currently consists of thirteen persons.
- New Status: The Board size will be reduced to ten persons.
- Effective Date: The change is effective April 29, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document solely reports the amendment to the by-laws.
Key Facts for Investor Verification
- Verify the effective date of the board size reduction (April 29, 2011).
- Confirm the new total number of directors (ten).
- Review the attached Exhibit 3.1 for the full text of the amended and restated By-Laws.